Jeffrey Hessekiel Sells 25,000 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock
Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) EVP Jeffrey Hessekiel sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $22.01, for a total value of $550,250.00. Following the transaction, the executive vice president now owns 583,345 shares of the company’s stock, valued at $12,839,423.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Jeffrey Hessekiel also recently made the following trade(s):
On Monday, December 4th, Jeffrey Hessekiel sold 25,000 shares of Exelixis stock. The stock was sold at an average price of $22.06, for a total value of $551,500.00. Exelixis Price Performance
NASDAQ:EXEL traded up $0.49 during trading hours on Monday, reaching $22.43. The company’s stock had a trading volume of 2,032,057 shares, compared to its average volume of 2,632,208. The company has a market cap of $6.98 billion, a price-to-earnings ratio of 80.11, a price-to-earnings-growth ratio of 1.24 and a beta of 0.57. Exelixis, Inc. has a one year low of $15.32 and a one year high of $22.80. The business’s 50-day moving average is $21.25 and its 200-day moving average is $20.64.
Exelixis (NASDAQ:EXEL – Get Free Report) last issued its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported $0.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.07). The business had revenue of $471.90 million during the quarter, compared to the consensus estimate of $473.31 million. Exelixis had a return on equity of 3.71% and a net margin of 5.19%. The company’s revenue for the quarter was up 14.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.23 earnings per share. On average, sell-side analysts predict that Exelixis, Inc. will post 0.6 EPS for the current fiscal year.
Institutional Investors Weigh In On Exelixis
Large investors have recently bought and sold shares of the business. Massmutual Trust Co. FSB ADV boosted its holdings in Exelixis by 189.7% during the second quarter. Massmutual Trust Co. FSB ADV now owns 1,440 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 943 shares during the period. Bank of New York Mellon Corp boosted its holdings in Exelixis by 3.5% during the second quarter. Bank of New York Mellon Corp now owns 3,132,198 shares of the biotechnology company’s stock valued at $59,856,000 after acquiring an additional 107,204 shares during the period. Geode Capital Management LLC boosted its holdings in Exelixis by 5.6% during the second quarter. Geode Capital Management LLC now owns 5,033,503 shares of the biotechnology company’s stock valued at $96,190,000 after acquiring an additional 265,404 shares during the period. Brandywine Global Investment Management LLC bought a new stake in Exelixis during the first quarter valued at about $17,350,000. Finally, Parallel Advisors LLC boosted its holdings in Exelixis by 52.8% during the second quarter. Parallel Advisors LLC now owns 1,809 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 625 shares during the period. 93.09% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of equities research analysts have weighed in on the company. TheStreet downgraded Exelixis from a “b” rating to a “c+” rating in a research report on Monday, October 9th. Leerink Partnrs restated a “market perform” rating on shares of Exelixis in a research report on Tuesday, August 8th. HC Wainwright started coverage on Exelixis in a research report on Tuesday, September 26th. They issued a “buy” rating and a $28.00 target price for the company. William Blair reaffirmed an “outperform” rating on shares of Exelixis in a report on Monday, October 23rd. Finally, SVB Leerink started coverage on shares of Exelixis in a research note on Tuesday, August 8th. They set a “market perform” rating and a $18.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $25.44.
View Our Latest Analysis on Exelixis
About Exelixis (Get Free Report)
Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Exelixis, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Exelixis wasn’t on the list.
While Exelixis currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Wondering when you’ll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Original: MarketBeat News Feed: Jeffrey Hessekiel Sells 25,000 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock